Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

However, on the same day, Jefferies maintained a Buy rating on Amgen (NASDAQ: AMGN). Based on Amgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of ...

CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have ...

However, today, Truist Financial assigned a Hold rating to Amgen (NASDAQ: AMGN). Based on Amgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue ...

Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

Currently, only 21% of Wall Street analysts have Palantir ranked a "buy". This makes Palantir the lowest recommended, best ...

U.S. stocks were lower after the close on Friday, as losses in the Technology, Healthcare and Consumer Services sectors led ...